Brutalist Biotech

• NIH fires exec amid probe into wife’s role in $3.3M contract: report (1h)
• Kezar sees hepatitis hold lifted, hints at resurrecting lupus program (2h)
• Repare finds suitor for paused PKMYT1 inhibitor in current partner Debiopharm (5h)
• AstraZeneca’s AL amyloidosis drug fails to reduce mortality in phase 3 test (6h)
• GSK telegraphs 'very limited number' of job cuts amid R&D investment spree (19h)

• 33 states pick up CMS program to pay for sickle cell gene therapies (55m)
• Cancer drugmaker LaNova to sell to China’s Sino Biopharm (1d)
• Hengrui, Kailera say dual-acting obesity shot succeeds in China study (1d)
• Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug (1d)
• AstraZeneca blood pressure drug succeeds in late-stage trial (2d)

• PureTech CEO leaves just one week after longtime chair steps down (12m)
• RFK replaces two top aides at HHS, including chief of staff (13m)
• Prime Medicine CSO departs, reveals new funding; FDA lifts partial hold on Kezar drug (33m)
• Endpoints livestream: Drugs and biomanufacturing in space with Varda CSO Adrian Radocea (1h)
• #IAS25: Jeanne Marrazzo, NIAID director placed on leave, on 'biggest threats' to HIV medicine (1h)

• AstraZeneca’s Amyloidosis Asset Stumbles in Late-Stage Trials (20m)
• J&J Raises 2025 Outlook as Oncology and Neuroscience Drive Q2 Growth (1h)
• GSK’s Blenrep DREAMMs Turn Fitful as FDA Questions Comeback in Multiple Myeloma (2h)
• Merck, AstraZeneca Cancer Collaborator Gets Swallowed Up by Sino Biopharm (2h)
• Vinay Prasad Overruled Reviewers on Moderna’s COVID-19 Shot for Kids (3h)

Bio IT World

• A Popular Alzheimer’s Biomarker Found at High Levels in Newborns (10h)
• Pharma Companies Finding Their Way with AI (1d)
• Trends from the Trenches: What a TV Scientist Knows About Teaching Science (6d)
• From Physics to Longevity: How Gero’s ProtoBind-Diff Tool Reads Nature’s Hidden Drug Library (1w)
• Population Genomics Projects Around the World Gaining Ground (1w)

• Protein structure competition, of AlphaFold fame, nearing deal to replace lost NIH funding (26m)
• An unusual use for AI in medical education (55m)
• FDA questions safety of GSK’s multiple myeloma drug (1h)
• International consortium uncovers protein changes linked to neurodegenerative disease (1h)
• We’re reading about Trump and pharma tariffs, an abortion pill ruling, and more (2h)

• Google Expands MedGemma Collection With Multimodal Health AI Models for Open Development (6d)
• Xaira Therapeutics Appoints Biotech Exec Behind Belharra and Ambys as President and COO to Scale AI-Driven Drug Discovery Platform (7d)
• NIH To End Funding for Animal-Only Studies, Backing Shift to New Approach Methodologies (1w)
• datma Launches Free Tool for Pharma to Assess Biomarker Coverage in Federated RWD (1w)
• AbbVie Acquires Capstan Therapeutics for $2.1B, Gaining In Vivo CAR-T Platform Targeting Autoimmune Diseases (2w)

• Eight rare autoimmune diseases biotechs are fighting to treat (2h)
• Serial acquirer Concentra Biosciences on a buyout spree in 2025 (1d)
• Top biotech books of all time (2d)
• XOMA Royalty’s acquisition of Turnstone Biologics: what do royalty deals offer the biopharma industry? (5d)
• How OMass Therapeutics is tackling congenital adrenal hyperplasia, a rare genetic disorder (5d)

• New Voltage Sensing Technology Images Brain Activity to Understand Disease (10m)
• NIST Releases Pancreatic Cancer Panacea of Genomic Content (3h)
• NIST Releases Entire Genetic Content of Pancreatic Cancer Cell Analyzed Using Multiple Technologies (3h)
• AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+ (16h)
• Global Neurodegeneration Proteomics Consortium Uncovers Biomarkers and Mechanisms (1d)

• How Outpatient CAR T-Cell Therapy May Be Safer For Patients (2h)
• How Love Helped Me Face Leukemia and Keep Living (18h)
• How Biomarker Testing Can Inform Metastatic Breast Cancer Care (19h)
• Coping With a Rare Cancer Diagnosis, Like GIST (20h)
• Refining Treatment Approaches and Advancements in High-Risk Melanoma (22h)

Contract Pharma*

• Tobin Scientific Opens New cGMP Warehouse in Wilmington, MA (49m)
• Satellos Appoints Wildon Farwell as Chief Medical Officer (1h)
• LogiCare3PL Partners with ChiRhoClin (1h)
• FDA Accepts Biologics License for Proposed Biosimilar to Simponi (1h)
• Thermo Fisher Scientific, Sanofi Expand Strategic Partnership (2h)

• North East NHS launches digital platform to tackle chronic kidney disease (2h)
• Proximie and HistoSonics partner to transform liver tumour treatment in US (2h)
• NHS England secures access to new cystic fibrosis treatment ALYFTREK (1d)
• MHRA approves first oral treatment for hereditary angioedema attacks (1d)
• Pierre Fabre secures China approval for BRAFTOVI combination in colorectal cancer (2d)

• The Crisis That Unites Us: Healthcare Costs Are Breaking Everyone (1h)
• Men’s Health is an Overlooked Part of Family Health: Why Employers Should Rethink Their Benefits Strategy (2h)
• Using Case Management to Improve Maternal Health Outcomes (3h)
• Report: Majority of Medicare Advantage Markets Lack Competition (16h)
• How Allina Health Is Modernizing Its Supply Chain Strategy (18h)

• How to successfully work with difficult people (3h)
• Waters to acquire BD flow cytometry business in a deal valued at $17.5 billion (19h)
• AI tool uses team approach to solve quantum chemistry problems (1d)
• ‘We have committed ourselves to this toxicity’ (1d)
• Team USA brings home gold at 57th International Chemistry Olympiad (1d)

The Pharma Letter*

• Lilly’s $1 billion CRISPR bet: what Verve means for gene editing (1h)
• PureTech CEO Bharatt Chowrira steps down (1h)
• Number of patent disputes continue to grow in Russian pharma market (1h)
• Amvuttra gains UK approval for heart form of ATTR amyloidosis (2h)
• Phase III trial miss for AstraZeneca’s anselamimab (3h)

• Across Cancer Types, Trispecific Antibodies Show Promise in Early Result (10m)
• Dual Bispecific Therapy Shows Promise in High-Risk Multiple Myeloma With EMD (1h)
• Addressing Financial Toxicity and Food Insecurity in Cancer Care (2h)
• Awareness of TIL Therapy for Melanoma Is Crucial for Timely Referral (20h)
• Medina on Patient Selection for Lifileucel in Melanoma (21h)

• Lawsuits rain down on Hims & Hers after Novo Nordisk partnership ends (1h)
• Johnson & Johnson surprises with higher Darzalex sales – share price rises (4h)
• EU Commission makes final verdict in price cartel case (4h)
• The FDA approves another Novolog copy (5h)
• Investor on Leo Pharma's new acquisition: "It's not like the market is thinking wow" (7h)

• Dual Antibody Conjugates For Twice the Excitement (17h)
• Sulfonate Esters in Drug Substances: Real Problem or Not? (1d)
• Senolytic Update (5d)
• Hexanitrogen Energies (6d)
• Thinking About Covalent Drug Reactivity (1w)

• NHS trust rolls out digital health tool for kidney disease (2h)
• FDA fast-tracks Sanofi's gene therapy for eye disease GA (3h)
• AstraZeneca sifts for efficacy crumbs in amyloidosis trial (4h)
• MSD, AZ partner LaNova bought by Sino Biopharm for $951m (5h)
• HHS layoffs are finalised as thousands of pink slips arrive (6h)

• Guide: 10 practical tips for reliable MEA experiments in preclinical neuroscience (1h)
• Webinar: The strategic power of pathology and AI for biopharma RD (3h)
• 10 practical tips for reliable MEA experiments in preclinical neuroscience (4h)
• From the Editor: Not NICE enough (5h)
• New optogenetic screening platform for drug discovery (5h)

Google News Biotech

• MEPs signal backing for public-private deals amid biotech report rewrite - Euractiv (11m)
• Generation Bio Surges 17% Amid Biotech Breakthrough Buzz – What’s Next? - AInvest (36m)
• China's domestic biotech industry is becoming a global force - China Daily - Global Edition (56m)
• Biotech company licenses new microbiome-sparing antibiotic developed at Illinois - Carle Illinois College of Medicine (1h)
• Lilly’s $1 billion CRISPR bet: what Verve means for gene editing (1h)